Cargando…

S123: ACUTE MYELOID LEUKEMIA STEM CELL SUBTYPES DEFINED BY MUTATIONS AND DIFFERENTIATION STATE REGULATE APOPTOTIC DEPENDENCY AND CLINICAL RESPONSE TO VENETOCLAX.

Detalles Bibliográficos
Autores principales:	Waclawiczek, Alexander, Leppä, Aino-Maija, Renders, Simon, Betz, Barbara, Stumpf, Karolin, Jansen, Maike, Merbach, Anne Kathrin, Shahswar, Rabia, Röllig, Christoph, Heuser, Michael, Sauer, Tim, Müller-Tidow, Carsten, Trumpp, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428283/ http://dx.doi.org/10.1097/01.HS9.0000967404.67012.e0

Ejemplares similares

P408: COMBINATORIAL BCL-2 FAMILY EXPRESSION IN ACUTE MYELOID LEUKEMIA STEM CELLS PREDICTS CLINICAL RESPONSE TO AZACITIDINE/VENETOCLAX
por: Renders, Simon, et al.
Publicado: (2023)

Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
por: Waclawiczek, Alexander, et al.
Publicado: (2023)

The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia
por: Weidenauer, Katharina, et al.
Publicado: (2023)

Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up
por: Shahswar, Rabia, et al.
Publicado: (2020)

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2020)

P453: NOVEL INSIGHTS INTO MINIMAL RESIDUAL DISEASE OF ACUTE MYELOID LEUKEMIA USING PRIMARY SAMPLES AND A CLINICALLY RELEVANT PDX MODEL.
por: Aroua, Nesrine, et al.
Publicado: (2023)

P510: PREDICTORS OF RESPONSE AND OUTCOME IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA RECEIVING VENETOCLAX WITH NON-INTENSIVE CHEMOTHERAPY
por: Krüger, Katja, et al.
Publicado: (2023)

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
por: Allert, Catana, et al.
Publicado: (2022)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
por: Kielbassa, Karoline, et al.
Publicado: (2023)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

P438: INTRACELLULAR CITRATE LEVELS MODULATE ANTI-APOPTOTIC PROTEINS TO ENHANCE VENETOCLAX SENSITIVITY IN ACUTE MYELOID LEUKEMIA STEM CELLS
por: Demir, Aykut, et al.
Publicado: (2023)

S123. EARLY DETECTION OF PSYCHOSIS: DIAGNOSTIC TRAJECTORIES
por: Lindhardt, Line, et al.
Publicado: (2020)

Hymeglusin Enhances the Pro-Apoptotic Effects of Venetoclax in Acute Myeloid Leukemia
por: Zhou, Cheng, et al.
Publicado: (2022)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
por: Urban, Aleksandra, et al.
Publicado: (2023)

S310: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP
por: Pratz, Keith, et al.
Publicado: (2023)

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2023)

T123. RISK FACTORS FOR PSYCHOTIC DISORDERS WITHIN MIGRANT GROUPS IN CANADA
por: Anderson, Kelly, et al.
Publicado: (2020)

S227: INITIAL SAFETY DATA FROM THE PHASE 3 POLAR BEAR TRIAL IN ELDERLY OR FRAIL PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA, COMPARING R-POLA-MINI-CHP AND R-MINI-CHOP
por: Jerkeman, Mats, et al.
Publicado: (2023)

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
por: Garcia-Manero, G., et al.
Publicado: (2022)

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
por: Kater, Arnon, et al.
Publicado: (2023)

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
por: Kater, Arnon, et al.
Publicado: (2023)

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
por: Miguel Bergua Burgues, Juan, et al.
Publicado: (2023)

O.5.1-10 Promoting mobility among wellbeing employees in Lahti, Finland
por: Hämäläinen, Riitta-Maija
Publicado: (2023)

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
por: Popovic, Relja, et al.
Publicado: (2021)

S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
por: Pemmaraju, Naveen, et al.
Publicado: (2023)

M123. EPISODIC VERBAL MEMORY DEFICIT IN SCHIZOPHRENIA: A MARKER OF PROGRESSION OF DISEASE OR DIFFERENT NEURODEVELOPMENTAL PATHWAYS FROM THE ONSET?
por: Reckziegel, Ramiro, et al.
Publicado: (2020)

Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination
por: Lew, Thomas E., et al.
Publicado: (2022)

S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Bill, Marius, et al.
Publicado: (2023)

Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells
por: Yang, Mingya, et al.
Publicado: (2020)

O4-7 An alternative framework for HEPA projects: Developing recommendations for the use of the Capability Approach
por: Till, Maike, et al.
Publicado: (2022)

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
por: Sureda, Anna, et al.
Publicado: (2023)

Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
por: Popescu, Bogdan, et al.
Publicado: (2023)

O4-8 Measuring capabilities for physical activity-related health outcomes: A Systematic review
por: Till, Maike, et al.
Publicado: (2022)

O.2.2-5 Health promotion in rural areas. Findings from two German projects on physical activity promotion among disadvantaged populations
por: Fleuren, Tobias, et al.
Publicado: (2023)

S4. IDENTIFYING HETEROGENEITY IN SYMPTOM NETWORKS IN THE GENERAL POPULATION: A RECURSIVE PARTITIONING APPROACH
por: Betz, Linda, et al.
Publicado: (2020)

O.4.4-11 Must we tell people to be less active to save the planet? The dilemma of physical activity promotion from a holistic health perspective
por: Gelius, Peter, et al.
Publicado: (2023)

O.6.3-8 The challenge of participatory projects for physical activity promotion: what to scale and how to scale?
por: Sommer, Raluca, et al.
Publicado: (2023)

ADDRESSING THE THEORETICAL GAPS IN ELDER FAMILY FINANCIAL EXPLOITATION
por: Gilligan, Megan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_urvovjq22u3pgb47tq2ud0cpga